Effects of an Oxymizer on Endurance Time in Patients With Chronic Lung Diseases

Effects of an Oxymizer Versus Conventional Nasal Cannula on Endurance Time in Patients With Chronic Obstructive Pulmonary Disease IV (COPD) or Interstitial Lung Disease (ILD)

Status

Completed

Phases

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT01713413

Enrollment

Registered

2012-10-24

Start date

2012-02-29

Completion date

2014-03-31

Last updated

2014-04-15

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

COPD, Interstitial Lung Disease

Keywords

Oxymizer, endurance time, exercise test, nasal cannula, COPD, ILD, oxygenation

Brief summary

The Oxymizer pendant® is a special oxygen cannula that can be used to supply high flow long term oxygen therapy. It is compatible with a wide variety of oxygen sources. In a reservoir, the Oxymizer® stores pure oxygen so that the concentration of inhaled oxygen is increased. The aim of this study is to investigate the potential benefit of the Oxymizer® with regard to the blood oxygenation during exercise testing. Given that the endurance time is very sensitive for little changes in exercise capacity, this test will be used to show the difference between the Oxymizer® and a conventional nasal cannula regarding exercise duration at 70% of peak Watt and oxygenation. The tests will be accompanied by blood gas analysis, partial pressure of carbon dioxide and heart rate.

Interventions

DEVICEOxymizer

Using first the Oxymizer and 24 h later the conventional nasal cannula.

DEVICEconventional nasal cannula

Using first the conventional nasal cannula and 24h later the Oxymizer

Study design

Allocation

RANDOMIZED

Intervention model

CROSSOVER

Primary purpose

TREATMENT

Masking

NONE

Eligibility

Sex/Gender

ALL

Age

18 Years to 75 Years

Healthy volunteers

Inclusion criteria

* COPD IV * interstitial lung disease * long-term oxygen therapy with oxygen flow rate \>= 2 L/min

Exclusion criteria

* acute cardial decompensation * usual kontraindication for exposure test (higher-grad Hypertension (arterial and pulmonal), cardiac valve vitien, instabile angina pectoris, cardiac arrhythmia)

Design outcomes

Primary

Measure	Time frame
Difference between Endurance time with Oxymizer and conventional nasal cannula	From starting until stopping cycling, up to 60 minutes

Secondary

Measure	Time frame	Description
Difference in oxygen saturation with Oxymizer and with conventional nasal cannula	stopping cycling, up to 60 minutes	—
Difference in PaCO2 with Oxymizer and with conventional nasal cannula	Stopping cycling, up to 60 minutes	measured by Sentec device

Countries

Germany

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026